PERGOVERIS

This brand name is authorized in Australia, Austria, Brazil, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug PERGOVERIS contains a combination of these active pharmaceutical ingredients (APIs):

1	Follitropin alfa UNII 076WHW89TW - FOLLITROPIN
	In women, the most important effect resulting from parenteral administration of FSH is the development of mature Graafian follicles.
	Read more about Follitropin alfa
2	Lutropin alfa UNII 3JGY52XJNA - LUTROPIN ALFA
	Lutropin alfa is a recombinant human Luteinising Hormone (r-hLH). Luteinising Hormone (LH) binds on the ovarian theca (and granulosa) cells and testicular Leydig cells, to a receptor shared with human chorionic gonadotropin hormone (hCG). Lutropin alfa in association with a Follicle Stimulating Hormone (FSH) preparation is recommended for the stimulation of follicular development in adult women with severe Luteinising Hormone (LH) and FSH deficiency.
	Read more about Lutropin alfa

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03GA05	Follitropin alfa	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03G Gonadotropins and other ovulation stimulants → G03GA Gonadotropins
Discover more medicines within G03GA05
G03GA07	Lutropin alfa	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03G Gonadotropins and other ovulation stimulants → G03GA Gonadotropins
Discover more medicines within G03GA07
G03GA30	Combinations	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03G Gonadotropins and other ovulation stimulants → G03GA Gonadotropins
Discover more medicines within G03GA30

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11667C
BR	Câmara de Regulação do Mercado de Medicamentos	525419030052007, 525419030052107, 525419030052207, 525421101110319
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	187-MBE-0421, 29576-01-11
EE	Ravimiamet	1327834, 1327845, 1327856, 1744994, 1745007, 1745018
ES	Centro de información online de medicamentos de la AEMPS	07396001, 07396003, 107396002, 107396004, 107396005, 107396006
FI	Lääkealan turvallisuus- ja kehittämiskeskus	040839, 098486, 098504, 150360, 398493
FR	Base de données publique des médicaments	63011177, 64102427, 67877476
GB	Medicines & Healthcare Products Regulatory Agency	124982, 387808, 387823
HK	Department of Health Drug Office	60335, 65978, 65979, 65980
IE	Health Products Regulatory Authority	88839, 89026
IL	מִשְׂרַד הַבְּרִיאוּת	6749, 8403, 8404, 8405
IT	Agenzia del Farmaco	038085015, 038085027, 038085039, 038085041, 038085054, 038085066
LT	Valstybinė vaistų kontrolės tarnyba	1030197, 1030198, 1030199, 1083150, 1083151, 1083152
NL	Z-Index G-Standaard	15008355
NL	Z-Index G-Standaard, PRK	105988, 148652, 148660, 148679
NZ	Medicines and Medical Devices Safety Authority	14283
PL	Rejestru Produktów Leczniczych	100180482, 100388350, 100388366, 100388372
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65138001, W65138002, W65138003, W65139001, W65140001, W65141001
SG	Health Sciences Authority	13990P, 15711P, 15712P, 15713P
TN	Direction de la Pharmacie et du Médicament	4703041
TR	İlaç ve Tıbbi Cihaz Kurumu	8699777790324, 8699777790331, 8699777790348
ZA	Health Products Regulatory Authority	44/21.10/0781